DM 치료의 혈당강화효과 비교

How much lowering of glycosylated hemoglobin (HbA1c) levels should we expect when we prescribe metformin to patients with diabetes? To answer this question, researchers performed a meta-analysis of 35 randomized metformin trials of ≥12 weeks' duration. Key findings are as follows:

• In comparisons between metformin monotherapy and placebo (or no drug treatment), metformin reduced mean HbA1c level by 1.1%.

• In comparisons involving metformin plus another oral agent versus the other agent alone, addition of metformin reduced mean HbA1c level by 1.0%.

• In comparisons involving metformin plus insulin versus insulin alone, addition of metformin reduced mean HbA1c level by 0.8% in patients with type 2 diabetes. In patients with type 1 diabetes receiving insulin, add-on metformin therapy had no HbA1c-lowering effect.

• In comparisons between low-dose and high-dose metformin (usually 1000 vs. 2000 mg daily), HbA1clevel was 0.3% lower with high-dose therapy.

quantifying the effect of metformin treatment and dose on glycemic control.pdf

DPP-IV inhibitor는 HbA1c 0.8% 정도 떨어뜨림.